Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARK Study: Fruquintinib + irinotecan hydrochloride liposome + capecitabine vs bevacizumab + chemotherapy for second-line metastatic colorectal cancer
ChiCTR2500105670Phase 4Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Jul 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of fruquintinib in metastatic colon cancer (mCRC) (3 arms), sponsored by Tongji Hospital. Primary endpoint: Progression-free survival (PFS). Planned start Jul 2025; status: not yet recruiting.
02
Drugs
fruquintinib
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on ChiCTR2500105670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105670.